Surefire Medical introduces infusion system for small vessel interventional procedures

20 October 2013 (Last Updated October 20th, 2013 18:30)

US-based developer of cancer-drug delivery catheters Surefire Medical has launched its Surefire Infusion System mT, designed to treat vessels as small as 2mm-3.5mm in interventional direct-to-target embolisation procedures.

US-based developer of cancer-drug delivery catheters Surefire Medical has launched its Surefire Infusion System mT, designed to treat vessels as small as 2mm-3.5mm in interventional direct-to-target embolisation procedures.

The mT incorporates Surefire's new low profile, effortlessly deployed expandable tip technology for maximum dose delivery without reflux.

Surefire Infusion System has been designed to enhance the accuracy and delivery of drugs directly to tumours.

When deployed, the tip dynamically responds to flow conditions to enable more of the embolic agent to reach the intended destination, while reducing non-target delivery compared to traditional infusion systems.

The newly designed mT infusion system catheter tip is designed with a smooth catheter inner liner for consistent dose delivery.

It is also designed to increase infusion efficiency of the device, while maintaining sufficient antegrade flow as small as 2mm.

"In a recent case, there was no way I could have delivered any dose safely without the mT because it was a small vessel with slow flow in a very high risk territory."

Other enhancements include thinner and more streamlined design for improved deployment and retraction; optimised shape of the Surefire expandable tip for reliable infusion even in very tortuous anatomy.

In addition to Surefire Infusion System mT, other infusion systems, including the ST/LT, will also incorporate many of the enhancements, the company reported.

Our Lady of the Lake Regional Medical Center Majoria chief of interventional radiology and interventional oncology Dr Ryan Majoria said the new Surefire Infusion System mT gives Interventional Radiologists greater ability to maximise targeted delivery in a wider range of patient candidates.

"In a recent case, there was no way I could have delivered any dose safely without the mT because it was a small vessel with slow flow in a very high risk territory," Dr Majoria said.

Surefire Medical has received regulatory approval for its Surefire Infusion System mT/ST/LT and specialty catheters in the US, Europe, Canada and New Zealand.

Surefire Medical president and CEO Jim Chomas said: "The advances our team implemented in the new Surefire Infusion System mT and our other products provide physicians with even greater assurance that targeted embolization procedures can be effectively deployed in difficult-to-treat patients who can now also benefit from direct-to-tumour therapies."

According to GlobalData estimates, the US infusion systems market was valued at $2.68bn in 2012 and is expected to grow at a CAGR of 3.5% to reach $3.41bn by 2019.